He found the treatment that already worked for anxious kids. Then he spent a decade learning how to make it reach them.
CEO & Co-Founder, InStride Health · Boston, MA
The operator's face: half spreadsheet, half mission statement.
There is a particular kind of waitlist that haunts families: the one for a child who is anxious now, in a way that bends the whole household out of shape, with the nearest evidence-based clinician booked solid for months and charging cash. John Voith built a company aimed squarely at that waitlist. InStride Health, where he is CEO and co-founder, does not try to invent a new cure for pediatric anxiety and OCD. It takes one that already works inside a hospital and figures out how to deliver it virtually, across a state, paid for by insurance instead of out of pocket.
That distinction - scale the proven thing, don't gamble on the novel one - is the whole personality of the company, and arguably of the founder. InStride's clinical engine is the McLean Anxiety Mastery Program, developed by his co-founders Dr. Mona Potter and Dr. Kathryn Boger, two clinicians who spent years refining group-based cognitive behavioral therapy with exposure and response prevention at McLean Hospital. Voith's job was never to second-guess the medicine. It was to wrap the medicine in a company that could survive contact with insurers, geography, and growth.
He came to it with an unusually specific resume for the task. Voith rose from intern to general manager at athenahealth, the company that made its name untangling the plumbing of American healthcare. There he ran interoperability - patient record sharing, closed-loop ordering, scheduling - the deeply unglamorous machinery that decides whether care actually moves from one place to another. If you wanted to design a training program for someone who would later have to make a hospital protocol travel through a virtual network and a billing system, you could hardly do better.
Before InStride, he tested the thesis once already. In 2017 he co-founded Virtudent, a teledentistry company, starting as COO and finishing as CEO. Dental care is not mental health, but the structural problem rhymes: take care that usually requires a specific chair in a specific building, and find a way to bring it to people who can't easily get there. Virtudent was the rehearsal. InStride is the performance with higher stakes.
When InStride launched publicly in October 2022, it did so with $26 million and a vow that sounded almost modest next to the usual startup bravado: scale a care model that already had outcomes data behind it. Voith's framing of the market was characteristically flat and unromantic. "There's a shortage of providers who provide evidence-based care," he said - not a shortage of need, not a shortage of apps, but a shortage of people delivering the treatment that actually moves the numbers. By 2024 the company had raised $56 million in total, with backers including General Catalyst, .406 Ventures, Valtruis, Mass General Brigham Ventures, and the Hopelab Foundation.
The numbers InStride reports are the kind that justify the whole detour through insurance contracts and clinician hiring: a reported 97% of program graduates show clinical improvement, 81% of caregivers report reduced strain, and 98% say they would recommend it. Early data put the average reduction in anxiety symptoms around 48% after eight to twelve weeks. For a founder whose first operating principle is to know the numbers, these are the ones that matter.
"Get behind a mission you believe in and surround yourself with people who do the same." — John Voith
Ask most founders for an operating creed and you get a slogan. Voith's comes with a built-in caveat, which is the interesting part. His advice is to "know the numbers in your business as early and often as possible" - and then, in the same breath, to know "there are eventually limits to measurement where qualitative information is better and faster."
It is a strange thing for a metrics person to admit, and that is exactly why it lands. A founder who only loved dashboards would never warn you about them. The discipline here is not measuring everything; it is knowing the moment a number stops telling the truth and a conversation starts telling it faster. In a business built on clinical outcomes, that distinction is not academic. It is the difference between a company that optimizes the measurable and one that treats the patient.
He pairs this with a blunt read on what building actually costs. "Innovating is hard and takes a lot of work," he has said - which is why the mission and the people around it are not soft extras but load-bearing. The Roosevelt passage he keeps close, about the credit belonging to the one "actually in the arena, whose face is marred by dust and sweat and blood," is less a motivational poster than a warning label.
Figures reported by InStride Health from program outcomes.
Few founders accumulate this much classroom before the arena. Voith ran the table on healthcare and policy education - and then, by his own telling, learned that innovating is mostly work, not coursework.
He keeps Theodore Roosevelt's "man in the arena" passage close - the one about the face marred by dust and sweat and blood. For Voith it reads less like inspiration and more like a job description.
Early on, he and his co-founders attempted a kayaking trip together. Whether you can weather a hard thing with someone tells you a lot before the cap table ever does.
Asked who he'd most want to meet, he names the longtime Disney chief - to learn how a leader protects quality while still running the business hard.
Consulting, athenahealth, teledentistry, pediatric mental health. Four chapters, one subject. He has never once wandered out of the field.
He loves numbers enough to warn you about them - flagging the exact point where a spreadsheet stops being honest and a conversation takes over.
He built around the people who created the treatment, not the other way around. Drs. Potter and Boger brought the program; he brought the company that could carry it.
"There's a shortage of providers who provide evidence-based care." — John Voith, on the real bottleneck